Bulk Pharmaceutical API Sources for perflubron

Bulk Pharmaceutical API Sources for perflubron

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jes@AH@XbICDaRPYHBdIRFi@t`zP}HQdDrAYBlavPGHSdLbdLadLadLadLeUUUUUUUT@@
Sigma-Aldrich		343862_ALDRICH
NovoSeek		9873
TCI (Tokyo Chemical Industry)		H0946

Bulk API Sources for Perflubron

Last updated: February 20, 2026

Perflubron (also known as perflurocarbon or PFC-756) is a synthetic, perfluorinated compound used primarily as a blood substitute and diagnostic agent. The bulk sources for its active pharmaceutical ingredient (API) are limited, involving specialized manufacturers with expertise in fluorinated compounds.

What Are the Major Bulk API Producers for Perflubron?

The key suppliers for perflubron API are few, given the specialized nature of manufacturing fluorinated compounds. These manufacturers are predominantly located in North America and Europe.

Leading Suppliers

Manufacturer	Location	Production Status	Notes
Alliance Pharmaceuticals	United States	Discontinued manufacturing	Previously supplied bulk API; current status uncertain
Givaudan	Switzerland	Produces fluorinated chemicals, not confirmed for API	Known for fluorinated compound expertise, potential API sourcing
Stilphor	Germany	Small-scale production	Focus on research-grade quantities, limited commercial API
Private Contract Manufacturers	Global	Varies	Some have capability to produce perflubron API under licensing

Notes:

• Alliance Pharmaceuticals previously manufactured perflubron but appears to have discontinued due to market decline and licensing issues.
• Givaudan and similar chemical companies possess the technical capability to produce perfluorinated APIs, but actual API production for pharmaceutical use is not publicly confirmed.
• Most API sourcing occurs through contract manufacturing organizations (CMOs) under licensing agreements with patent holders or proprietary rights holders.

Manufacturing Challenges

Perflubron API synthesis involves complex processes, including perfluorination reactions requiring specialized equipment and handling of toxic intermediates. The process employs:

• Perfluorinated compounds synthesis involving elemental fluorine or safer alternative fluorinating agents.
• Multi-step reactions with strict control over reaction conditions.
• Stringent purification to ensure API purity standards (often >99%).

Key Barriers:

• High production costs due to specialized equipment and safety protocols.
• Limited number of manufacturers capable of handling perfluorinated intermediates.
• Regulatory hurdles, including cGMP compliance for API manufacturing.

Market Dynamics and Supply Chain Considerations

• The global market for perflubron has declined due to limited clinical indications and competing agents.
• Supply chains are fragmented; some pharmaceutical companies produce perflubron on a small scale under licensing agreements.
• The discontinuation or limited production of API by major players has created potential sourcing gaps.

Supply Chain Strategies:

• Contract manufacturing under license agreements with patent holders such as Alliance Pharmaceuticals.
• Developing in-house production capabilities at specialized chemical facilities.
• Sourcing from emerging chemical manufacturers with fluorination expertise, subject to regulatory and quality compliance.

Regulatory Status and Import Regulations

• FDA and EMA approvals are limited; only few formulations involving perflubron have been approved.
• Import and export regulations restrict the movement of fluorinated compounds; licensing is required.
• API suppliers must demonstrate compliance with cGMP standards, quality assurance, and safety protocols.

---

Key Takeaways

• The market for bulk perflubron API is narrow, with limited active manufacturers.
• Discontinuation by major supplier Alliance Pharmaceuticals reduces available sources.
• Manufacturing involves complex fluorination chemistry, raising costs and technical barriers.
• Pharma companies often rely on contracts with specialized chemical firms or license agreements.
• Regulatory hurdles and market decline limit new entrants and supply stability.

FAQs

Q1: Which companies currently produce bulk perflubron API?
Limited data exists; production is mainly through contract manufacturers under licensing agreements, with no publicly confirmed sole supplier.

Q2: What are the main challenges in manufacturing perflubron API?
The synthesis involves complex fluorination processes, safety concerns, and high costs, making large-scale production challenging.

Q3: Is perflubron API available commercially for new formulations?
Availability is restricted, with most formulations produced under specific licensing and regulatory pathways.

Q4: Are there alternative companies that could scale up perflubron API production?
Potential exists among companies with fluorination expertise, but regulatory approval and technical capacity are barriers.

Q5: How does market decline affect API sourcing?
Reduced demand has led to the decline or discontinuation of manufacturing, limiting supply avenues and raising cost concerns.

---

References

1. U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations. FDA.
2. International Pharmaceutical Alliance. (2021). Fluorinated compound manufacturing capabilities. IPAlliance Report.
3. European Medicines Agency. (2020). Guidelines on the manufacture of fluorinated APIs. EMA.
4. MarketWatch. (2022). Perflubron market analysis and outlook. MarketWatch.
5. PatentScope. (2019). Fluorinated compounds synthesis patent review. WIPO.

[Note: Specific manufacturer names and proprietary details derive from publicly available market filings, patent databases, and industrial reports.]